Senior Oncology CRC for mCRPC Trials – Flexible, Long-Term
Enregistrez cette offre et organisez votre recherche
Créez un compte gratuit pour enregistrer des offres d'emploi, créer des alertes et revenir à cette liste depuis votre tableau de bord.
En continuant, vous acceptez nos Conditions d’utilisation & Politique de confidentialité.
R&D Partners in Ghent, Belgium seeks an experienced Senior Clinical Research Coordinator for a flexible, long-term assignment focused on an mCRPC study. You will provide hands-on trial support at the site, working independently with minimal supervision and approximately one day per month of commitment.
The role emphasizes data entry, query resolution, data quality, and documentation. Experience in oncology and prostate cancer is highly valued.
-
Clinical Research Coordinator
Il y a 2 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique R&D Partners Temps plein 50 000 € - 65 000 € ContratAn experienced Oncology Clinical Research Coordinator looking for a flexible, long-term assignment where your expertise can make a direct impact on an important mCRPC study? We are looking for an experienced Senior Clinical Research Coordinator to provide ongoing, flexible support to a clinical research site in Ghent, Belgium. The assignment will support an...
-
Biostatistical Director
Il y a 4 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique argenx SE Temps plein 120 000 € - 180 000 € ContratJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to...
-
Biostatistical Director
Il y a 4 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique Argenx Temps plein 120 000 € - 180 000 € ContratJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to...